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Abstract
 
Thymic stromal lymphopoietin (TSLP) signals via a receptor comprising the interleukin (IL)-7
receptor 
 
  
 
chain and a distinctive subunit, TSLP receptor (TSLPR), which is most related to
the common cytokine receptor 
 
  
 
chain, 
 
 
 
c
 
. We have generated TSLPR knockout (KO) mice
and found that although these mice had normal lymphocyte numbers, 
 
 
 
c
 
/TSLPR double KO
mice had a greater lymphoid defect than 
 
 
 
c 
 
KO mice. This indicates that TSLP contributes to
lymphoid development and accounts for some of the residual lymphoid development in 
 
 
 
c 
 
KO
mice and presumably in patients with X-linked severe combined immunodeficiency. Injection
of TSLP into 
 
 
 
c 
 
KO mice induced the expansion of T and B cells. Moreover, sublethally irra-
diated TSLPR KO mice showed weaker recovery of lymphocyte populations than wild-type
(WT) littermates, even when neutralizing anti–IL-7 antibodies were injected. Interestingly,
TSLP preferentially stimulated the proliferation and survival of CD4
 
  
 
single positive thymocytes
and peripheral T cells in vitro. Additionally, CD4
 
  
 
T cells from TSLPR KO mice expanded
less efficiently than WT CD4
 
  
 
T cells in irradiated hosts, and TSLP preferentially expanded
CD4
 
  
 
T cells both in vitro and in vivo. Thus, as compared with other known cytokines, TSLP
is distinctive in exhibiting a lineage preference for the expansion and survival of CD4
 
  
 
T cells.
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Introduction
 
Cytokines regulate many aspects of the immune system, in-
cluding hematopoiesis, inflammation, and both innate and
acquired immunity (1). IL-7 plays a critical nonredundant
role in the development of T and B lymphocytes in mice (2,
3) and of T cells in humans (4). IL-7 KO mice display a
marked reduction in thymic cellularity, but maintain a normal
CD4:CD8 ratio. Their B cell development is also defective,
with a block in the BM at the transition point to pre–B cells
(between Hardy classification B and C fraction cells and
fraction D cells; reference 3). An even more severe B cell
phenotype is apparent in IL-7R
 
  
 
KO mice, where the block
is at the earlier transition from pre-pro–B cells to pro–B cells
(Hardy classification fraction B; reference 2). Like IL-7 KO
mice, IL-7R
 
  
 
KO mice exhibit severely reduced thymic
cellularity and defective T cell maturation (2, 3).
Thymic stromal lymphopoietin (TSLP) is a cytokine that
was originally identified as a growth factor in the supernatant
of the Z210R.1 thymic stromal cell line that could support
the development of immature NAG8/7 B cells to the
B220
 
 
 
/IgM
 
  
 
stage (5). Its biological actions were later
found to overlap with those of IL-7. Both cytokines promote
the maturation of B lymphocytes, with TSLP apparently
supporting growth to more mature stages than IL-7 (6).
TSLP has also been shown to be a regulator of dendritic
cell–mediated control of Th2 cell–biased human allergic
responses (7). Like IL-7, the TSLP receptor complex con-
tains IL-7R
 
 
 
 (8, 9). In addition, the TSLP receptor also
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contains a specific subunit, TSLPR, whereas the IL-7 re-
ceptor complex includes the common cytokine receptor 
 
 
 
chain, 
 
 
 
c
 
 (10, 11), which is also shared by the receptors for
IL-2, IL-4, IL-9, IL-15, and IL-21 (12). Both IL-7 and
TSLP activate Stat5a and Stat5b (13, 14). TSLPR is ex-
pressed in many tissues, including liver, brain, testis, BM,
and thymus.
To study the biological role of murine TSLP in vivo, we
generated TSLPR KO mice. These mice exhibited normal
T and B cell development and cellularity. However, mice
deficient in both TSLPR and 
 
 
 
c 
 
displayed more severe lym-
phoid defects than 
 
 
 
c 
 
KO mice. Consistent with a role for
TSLP in lymphoid development/expansion, sublethally ir-
radiated TSLPR KO mice showed weaker recovery of lym-
phocytes than WT controls. In addition, daily injection of
TSLP into 
 
 
 
c 
 
KO mice increased both thymic and splenic
cellularities by enhancing the expansion of both T and B
cells, with the accumulation of CD4
 
  
 
T cells in the periph-
ery. Moreover, TSLP could enhance TCR-induced expan-
sion of purified CD4
 
  
 
single positive (SP) thymocytes and
of splenic CD4
 
  
 
T cells. Finally, carboxyfluorescein succi-
nimidyl ester (CFSE)-based experiments showed TSLP-
dependent expansion of CD4
 
  
 
T cells both in vitro and in
vivo. These studies reveal an unexpected effect of murine
TSLP in the preferential expansion of CD4
 
  
 
T cells.
 
Materials and Methods
 
Generation of TSLPR
 
 
 
/
 
  
 
Mice.
 
TSLPR genomic DNA was
obtained from a P1 clone prepared from 129sv mice (Genome
Research). The targeting construct was designed to delete all exons
of the TSLPR gene and replace them with the neomycin resis-
tance gene (Neo; see Fig. 1). Embryonic stem (ES) cells were elec-
troporated with 50 
 
 
 
g of linearized targeting construct. Positive
and negative selection of transfected cells was conducted using 350
 
 
 
g/ml G418 (Life Technologies) and 2 
 
 
 
M gancyclovir (Sigma-
Aldrich), respectively. Of 800 ES clones screened, those that had
undergone homologous recombination were identified by South-
ern blotting, using probes located 5 and 3
 
  
 
to the targeting con-
struct. Mice were mated once with WT C57BL/6. The resulting
C57Bl6/129 mice were genotyped using three PCR primers:
primer A, 5
 
 
 
-AACCTCTCCCACAAGAAGTCCAGAAGT-3
 
 
 
;
Neo primer, 5
 
 
 
-ATCGCCTTCTATCGCCTTCTT-3
 
 
 
; and primer
B, 5
 
 
 
-AGACTTTACCTGATTCCTGCCTTG-3
 
 
 
.
Primers A and B amplify a 250-bp segment of the endogenous
TSLPR gene. The Neo primer and primer B identify the tar-
geted gene and give a 650-bp product. The probes for Southern
blots were generated using the Taq Gold kit (Applied Biosystems)
under the following conditions: 94
 
 
 
C for 2 min, 25 cycles of
94
 
 
 
C for 30 s, 58
 
 
 
C for 45 s, and 45
 
 
 
C for 45 s, and then 72
 
 
 
C
for 7 min before cooling to 4
 
 
 
C. Genotyping PCR reactions
were performed similarly, but 33 cycles instead of 25 were per-
formed using Ready-TO-Go PCR beads (Amersham Bio-
sciences). To determine TSLPR mRNA expression, total RNA
was isolated from the thymus using TRIzol (Promega). 1 
 
 
 
g
RNA per RT-PCR reaction was amplified using internal up-
stream (5
 
 
 
-GCGAGGGCGGGGCTGCTGGAG-3
 
 
 
) and down-
stream (5
 
 
 
-CCTGGCTGGCGGGGCTGTGGC-3
 
 
 
) primers
and an RNA PCR kit (Applied Biosystems). For Southern blots,
genomic DNA was digested as indicated in Fig. 1 and the probe
described above was used. Southern blot hybridization and wash-
ing were performed using QuickHyb (Stratagene). TSLPR
 
 
 
/
 
 
 
mice generated from two different ES clones showed no apparent
differences. All experiments were performed under protocols ap-
proved by the National Institutes of Health Animal Use and Care
Committee and followed the National Institutes of Health guide-
lines, Using Animals in Intramural Research. Unless indicated
otherwise, all mice analyzed were 6–8-wk-old littermates and
generally sex matched. No sex-related differences were observed
related to the studies performed.
To generate 
 
 
 
c
 
/TSLPR double KO (DKO) mice, TSLPR
KO females were mated to 
 
 
 
c 
 
KO males on a C57BL/6 back-
ground (backcrossed for 
 
 
 
15 generations). As 
 
 
 
c 
 
is on the X
chromosome, TSLPR
 
 
 
/
 
  
 
 
 
c
 
 
 
/
 
  
 
female and TSLPR
 
 
 
/
 
  
 
 
 
c
 
 
 
/Y 
 
male
F1 progeny were then mated. 
 
 
 
c
 
/TSLPR DKO and 
 
 
 
c 
 
KO litter-
mate progeny were then analyzed.
 
Injection of IL-7 and TSLP.
 
2-wk-old WT or 
 
 
 
c 
 
KO mice re-
ceived daily i.p. injections with 0.1 ml PBS alone or containing
0.5 
 
 
 
g murine IL-7 or TSLP for 1 and 3 wk so that mice were 3
or 5 wk old at the time of analysis.
 
Treatment with IL-7–neutralizing mAb.
 
8–10-wk-old WT and
TSLPR KO females were irradiated with 600 cGy of whole body
irradiation. Mice were injected three times a week for 4 wk with
1 mg of a control mAb or M25 anti–IL-7–neutralizing mAb (15).
 
Flow Cytometric Analyses.
 
Single cell suspensions were pre-
pared from the thymus, spleen, and BM. Cells were washed with
FACS
 
® 
 
buffer (PBS, pH 7.4, 0.5% BSA, 0.02% sodium azide).
10
 
6 
 
cells were treated with Fc-block (BD Biosciences) for 15 min,
and then incubated with the indicated fluorochrome-conjugated
antibodies (all from BD Biosciences) for 20 min. Cells were then
washed twice with FACS
 
®
 
 buffer and analyzed. To examine cell
death, a PE-conjugated annexin V kit (BD Biosciences) was used
according to the manufacturer’s instructions.
 
Measurement of IgM Levels.
 
Sera from 3-wk-old 
 
 
 
c 
 
KO and
 
 
 
c
 
/TSLPR DKO mouse littermates were analyzed for resting
IgM levels using a sandwich ELISA. In brief, 100 
 
 
 
l (2 
 
 
 
g/ml in
coating buffer: 0.15 M sodium carbonate, 0.35 M sodium bicar-
bonate, pH 9.5, 0.02% sodium azide) anti–mouse IgM capture
antibody (BD Biosciences) was used to coat 96-well plates (EIA
plates; Costar) overnight at 4
 
 
 
C. Wells were then coated with
blocking buffer (PBS supplemented with 10% FBS) for 1 h at
room temperature. Sera were diluted at 1:1,000 in blocking
buffer and incubated in the wells overnight at 4
 
 
 
C. Wells were
washed in PBS containing 0.1% Tween and then incubated with
a 1:2,000 dilution of secondary horseradish peroxidase–conju-
gated anti-IgM (BD Biosciences) for 1 h at room temperature.
The assay was ended by adding the substrate mixture (BD Bio-
sciences) and measuring absorbance at 450 nm.
 
Proliferation and Survival Assays.
 
To isolate CD4
 
  
 
and CD8
 
 
 
SP T cells, thymocytes were first incubated with anti-CD8
 
  
 
or
anti-CD4
 
  
 
paramagnetic beads, respectively, and the bound cells
were removed by passing the samples through the autoMACS sys-
tem (Miltenyi Biotec). The nonbound cells (negative eluted frac-
tion) were then treated with CD4
 
  
 
and CD8
 
  
 
paramagnetic beads
to separate CD4
 
  
 
and CD8
 
  
 
T cells, respectively, from the double
negative (DN) cells. Mature splenic CD4
 
  
 
and CD8
 
  
 
T cells were
isolated using their respective paramagnetic beads. Fresh thy-
mocytes and splenocytes were cultured for 48 h in RPMI 1640
medium containing 10% FBS, 2 mM 
 
l
 
-glutamine, and antibiotics,
in 96-well flat-bottom plates (2 
 
  
 
10
 
5 
 
cells/well) that were coated
or not with 2 
 
 
 
g/ml anti-CD3
 
  
 
(BD Biosciences). Cells were ad-
ditionally incubated with 100 ng/ml IL-7 or TSLP as indicated.
Wells were pulsed with 1 
 
 
 
Ci [
 
3
 
H]thymidine (6.7 Ci/mmol; 
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NEN Life Science Products) for the last 9 h of culture. Prolifera-
tion was also examined using 5  M CFSE labeling (Sigma-
Aldrich) for 10 min at 37 C. For in vivo proliferation, 0.8 mg
5-bromo-2 -deoxyuridine (BrdU; Sigma-Aldrich) was injected 16
and 10 h before the mice were killed. Levels of BrdU were deter-
mined using PE-conjugated antibodies (16). To examine the sur-
vival of thymocytes, cells were isolated and cultured as described
above for 1 wk, and the number of live cells was determined by
trypan blue exclusion and annexin V/7-AAD staining.
Adoptive Transfer of T Cells. C57BL/6  c KO mice were irra-
diated with 600 cGy of whole body irradiation. 8 h later, the
mice were injected with a single cell suspension of 8    106
splenic CD4  or CD8  T cells from WT or TSLPR KO mice
that were labeled with CFSE for 10 min at 37 C. Spleens were
analyzed on days 3 and 7 by flow cytometry.
Online Supplemental Material. Fig. S1 shows the effect of
TSLP on lymphopoiesis in WT mice. The flow cytometric anal-
ysis of the thymus and spleen 1 and 3 wk after injection of WT
mice with PBS, IL-7, or TSLP is shown. Thymocytes were
stained with anti-CD4 versus anti-CD8. Splenocytes were
stained with anti-CD4 versus anti-CD8 and anti-B220 versus
anti-IgM. Fig. S1 is available at http://www.jem.org/cgi/content/
full/jem.20031975/DC1.
Results
TSLPR KO Mice Exhibit Normal Lymphohematopoietic De-
velopment. To generate TSLPR KO mice, we used a tar-
geting vector designed to replace the TSLPR coding region
with the neomycin resistance cassette (Fig. 1 A). 4 clones out
of 800 showed homologous recombination as determined
using both 3  and 5  probes (Fig. 1 B and not depicted).
Two clones were used to generate chimeric mice, and het-
erozygous offspring corresponding to each clone were inter-
crossed to generate TSLPR KO mice as confirmed by PCR
genotyping and TSLPR mRNA expression (Fig. 1 C). The
progeny mice exhibited normal Mendelian ratios. 6–8-wk-
old TSLPR KO mice were indistinguishable from WT lit-
termates in viability, growth, development, and fertility. The
inactivation of TSLP signaling was confirmed by the defec-
tive response of TSLPR KO splenocytes compared with
WT splenocytes to treatment with anti-CD3 plus TSLP ver-
sus anti-CD3 alone (Fig. 1 D).
Thymus, spleen, and BM were similar in size and cell
number, and no differences in histology were observed
between TSLPR KO mice and WT littermates (not de-
picted). Analysis of TSLPR KO thymuses showed that the
DN, double positive (DP), and CD4  and CD8  SP T cells
were present in normal distributions (Fig. 1 E). B220 versus
anti-CD3 staining in the spleen was normal (not depicted),
as was the CD4:CD8 T cell ratio (Fig. 1 F, top). Moreover,
levels of both B220  IgM  immature cells and B220  IgM 
pre– and pro–B cells (both percent and absolute numbers)
were similar in TSLPR KO and WT mice in both spleen
(Fig. 1 F, bottom) and BM (Fig. 1 G). Surface levels of
CD3 , TCR- , TCR-  , CD4, CD5, CD8, CD11c,
CD21, CD23, CD43, CD44, CD62L, B220, IgM, IgD,
DX5, Gr1, TER119,  c, HSA, and BP-1, as well as IL-
7R , were comparable to those found in WT mice (not
depicted). Thus, although TSLP has been reported to affect
fetal lymphoid development (17), we found no overt de-
fects in adult lymphopoiesis in TSLPR KO mice. It is pos-
sible that TSLP serves a redundant role and that other cyto-
kines, especially the closely related IL-7, might compensate
for the absence of TSLP signal. No difference was observed
between WT and TSLPR KO mice in the number of col-
ony forming units (CFU-B and CFU-GM assays) from BM
cultures in vitro (not depicted). Although TSLPR is ex-
Figure 1. Normal immunological development in
TSLPR KO mice. (A) Schematic of the TSLPR tar-
geting strategy. The 6-kb BglII to Nhe I 5  and 3-kb
Pvu II 3  flanking regions of the TSLPR gene were
cloned 5  and 3  to the Neo gene. The targeting vector
was linearized, electroporated into ES cells, and trans-
fected clones were screened using 5 and 3   probes
(squares). (B) Southern hybridization of the ES clones.
The restriction enzymes and fragment sizes are indi-
cated ( / , WT;  / , heterozygote). (C) Genotyping
of the mice was performed as described in Materials
and Methods (left). RT-PCR was performed using
TSLPR internal primers to detect the TSLPR mRNA
transcript thymus (right). White lines indicate that inter-
vening lanes have been spliced out. (D) TSLP signifi-
cantly increased anti-CD3 –induced proliferation of
WT splenocytes (P   0.001), but not of TSLPR KO
splenocytes. Results are expressed as mean fold induc-
tion   SEM (n   14). (E–G) Flow cytometric analysis
showing no difference in the CD4/CD8 profile of the
total thymus (E, top), the CD25/CD44 profile of DN
thymocytes (E, bottom), or in the spleen (F) and BM
(G) of WT and TSLPR-deficient mice. Antibodies for
the CD4  and CD8  surface markers were used to
evaluate the T cell populations in the thymus (E) and
spleen (F, top), whereas antibodies for B220  and surface
IgM  were used to evaluate B cells populations in the
spleen (F, bottom) and BM (G).TSLP Promotes CD4  T Cell Development 162
pressed in various tissues, including brain, liver, and lung
(8), suggesting a possible role of TSLP in the physiological
functions of these organs, histopathological analysis of these
organs in TSLPR KO mice revealed no obvious abnormal-
ities (not depicted).
TSLP and IL-7 Exhibit Overlapping Actions In Vivo. Be-
cause TSLP and IL-7 share IL-7R  as a receptor compo-
nent, we compared the actions of these cytokines. Both
IL-7 and TSLP similarly increased thymic and splenic cel-
lularity in WT mice after 1 wk of daily injections (Fig. 2
A, left), with CD4 and CD8 T cell populations present
in normal ratios (Fig. S1 A, ii and iii vs. i, and v and vi
vs. iv, available at http://www.jem.org/cgi/content/full/
jem.20031975/DC1). Thus, thymic and splenic T cell
populations were all increased. In the spleen, TSLP and
IL-7 had similar abilities to increase B cells (Fig. S1 A, viii
and ix vs. vii), whereas TSLP was more potent in expand-
ing immature B220  IgMlow cells in the BM (Fig. 2 B, ii
and iii vs. i; see percentages for the different fractions of B
cells in Fig. 2 C). After 3 wk of treatment of WT mice
with TSLP or IL-7, the increase in thymic and splenic cel-
lularity was no longer statistically significant (Fig. 2 A,
right) and the CD4 :CD8  T cell ratio remained constant
(Fig. S1 B, ii and iii vs. i, and v and vi vs. iv), but the in-
crease in B cells was still evident in the spleen (Fig. S1 B,
viii and ix vs. vii) and BM (Fig. 2 B, v and vi vs. iv; see
percentages for the different fractions of B cells in Fig. 2
C). The consistent absolute decrease in B cells in WT ani-
mals between 1 and 3 wk of treatment presumably, at least
in part, reflects an age-dependent regulatory mechanism of
B cell expansion, as a decrease was even seen in the un-
treated control animals (Fig. 2 C). These results indicate
that both TSLP and IL-7 can promote lymphocyte expan-
sion. The normal levels of lymphocytes in TSLPR KO
Figure 2. TSLP can expand lymphocyte populations
in WT mice. (A) The absolute number of thymocytes,
splenocytes, and BM cells in WT mice injected daily
with PBS, IL-7, or TSLP for 1 and 3 wk. 1 wk of
treatment with TSLP and IL-7 increased thymic cellu-
larity (means   SEM of 204   46   106 and 195  
22   106 [P   0.01 and 0.001, respectively] vs. 139  
13   106 for the PBS-treated mice). 1 wk of treatment
with TSLP and IL-7 also increased splenic cellularity
(means   SEM of 126   23   106 and 118   13  
106 [P   0.004 and 0.002, respectively] vs. 80   12  
106 for the PBS-treated mice). No significant difference
was observed in the BM. After 3 wk of treatment with
TSLP or IL-7, the changes in cellularity of thymus,
spleen, and BM were not significant. (B) Flow cyto-
metric analysis of the BM 1 and 3 wk after injection of
WT mice with PBS, IL-7, or TSLP. (C) Percentages of
populations shown in B.
Figure 3. TSLP is critical for optimal lym-
phopoiesis in the presence and absence of IL-7. WT
and TSLPR KO mice were sublethally irradiated and
injected three times a week for 4 wk with 1 mg of
control or M25 anti–IL-7 mAbs. (A) TSLPR KO
treated with control or anti–IL-7 mAbs displayed
lower thymic cellularity (P   0.001 for both mAbs)
and splenic cellularity (P   0.03 for anti–IL-7 and
P   0.02 for control mAb) when compared with
WT littermates. (B) The absolute numbers of thymic
subpopulations, except for DN cells, were decreased
in TSLPR KO mice compared with WT mice (P  
0.05).  (C) The absolute numbers of CD4  and
CD8  T and B cells in the spleens of irradiated ani-
mals. Mice lacking TSLPR had fewer lymphocytes
than WT mice, when experiments were performed
with either control or anti–IL-7 mAbs (P   0.05).
(D) B220 versus CD19 flow cytometric analysis of
the spleen and BM from WT (top) and TSLPR
KO (bottom) mice.Al-Shami et al. 163
mice are presumably, in part or entirely, explained by the
continued action of IL-7.
TSLP Signaling Is Required for Efficient Recovery of Lympho-
cyte Populations after Sublethal Irradiation. To further exam-
ine the role of TSLP in lymphopoiesis, WT and TSLPR
KO mice were sublethally irradiated and their ability to re-
cover cellular populations was evaluated. In these experi-
ments, we included either a control mAb or neutralizing
mAb to IL-7. Irradiated WT animals treated with the con-
trol mAb recovered most of their thymic and splenic cellu-
larities within 4 wk, whereas TSLPR KO mice did not
(Fig. 3 A). Similarly, CD4  and CD8  T cell subpopula-
tions in the thymus (Fig. 3 B) and spleen (Fig. 3 C) were
lower in TSLPR KO mice than in WT littermates. B cell
recovery in TSLPR KO mice was also less efficient than in
WT mice (Fig. 3 C), and flow cytometric analysis of B cells
showed that B220  CD19  B cells were greatly diminished
in the spleens in TSLPR KO mice (Fig. 3 D). These results
establish a critical role for TSLP in mediating optimal T
and B cell lymphopoiesis in mice.
We also examined reconstitution in mice in which a
neutralizing mAb to IL-7 was injected (1 mg three times a
week for 4 wk; reference 15). As expected, treatment with
the anti–IL-7 mAb reduced lymphopoiesis in WT mice
(Fig. 3 A). Importantly, however, recovery was even more
impaired in TSLPR KO mice treated with anti–IL-7 mAb,
including impaired thymic and splenic cellularity (Fig. 3
A), with CD4  and CD8  T cell subpopulations in the thy-
mus (Fig. 3 B) and spleen (Fig. 3 C) being lower in TSLPR
KO mice than in WT littermates. No significant differ-
ences in the percentages of DN1, DN2, DN3, and DN4
cells were observed (not depicted). B cell recovery in
TSLPR KO mice was also less efficient than in WT mice
in the presence of anti–IL-7 mAb (Fig. 3, C and D, BM
and spleen). B220  CD19  B cells were nearly eliminated
in the BM in both WT and TSLPR KO mice treated with
anti–IL-7 (Fig. 3 D, far right panels). These results establish
a critical role for TSLP in mediating optimal T and B cell
lymphopoiesis in mice. Because recovery is less in the ab-
sence of signaling by TSLP plus IL-7 compared with the
absence of only IL-7, our data indicate a critical IL-7–inde-
pendent role for TSLP in recovering from lymphopenia.
 c/TSLPR DKO Mice Exhibit Greater Defects than  c KO
Mice, and TSLP Can Increase Cellularity in  c KO Mice.  c
KO mice have defective T and B cell development. We
hypothesized that a greater defect in  c/TSLPR DKO
mice than in  c single KO mice would suggest a role for
TSLP in contributing to the residual lymphoid develop-
ment that is present in  c KO mice and in humans with
XSCID, which results from mutations in  c (12). Indeed,
the low thymic cellularity observed in  c KO mice (18, 19)
was further diminished in  c/TSLPR DKO littermates
(Fig. 4 A). However, CD4  and CD8  SP, CD4  CD8 
DP, and CD4  CD8  DN T cells (DN1, DN2, DN3, and
DN4) were all present in  c/TSLPR DKO thymus at ratios
comparable to those in the thymus of  c KO mice (not de-
picted). Similarly, although total BM cellularity was greatly
reduced in  c/TSLPR DKO mice, a similar distribution of
B cells was present in the BM (Fig. 4 B) and spleen (not de-
picted) as were seen in  c KO mice. Specifically, B220 ver-
sus CD43 profiles were similar in both  c KO and the  c/
TSLPR DKO mice (Fig. 4 B, top), as was expression of
Figure 4. Comparison of the lymphoid develop-
ment in  c KO mice versus  c/TSLPR DKO mice.
(A)   c/TSLPR DKO mice had lower thymic,
spleen, and BM cellularities than  c KO mice (thy-
mus: mean   SEM of 12.3   6.7   106 for  c KO
mice vs. 5.7   4.5    106 for   c/TSLPR DKO
mice [P   0.009]; spleen: mean   SEM of 43  
17.7   106 for  c KO mice vs. 26.8   13.7   106
for   c/TSLPR DKO mice [P    0.02]; BM:
mean   SEM of 23.4   15.5   106 for  c KO
mice vs. 14.3   7.6   106 for  c/TSLPR DKO
mice [P   0.047]). All mice were age matched
and no sex-related differences were noted. (B) Flow
cytometric analysis of BM (top, B220 vs. CD43)
and peritoneal cavity lymphocytes (bottom, B220 vs.
CD5). (C) Similar levels of IgM in the serum of  c
KO and  c/TSLPR DKO mice. (D) Injection of
0.5   g/day of TSLP (open rectangles) enhances
lymphoid cellularity in  c KO mice. Treatment for
1 and 3 wk showed an enhanced cellularity in thy-
mus (mean   SEM of 7.8   2.9   106 for PBS-
injected mice vs. 32   10   106 for TSLP-injected
mice [P   0.0001] after 1 wk of treatment and a
mean   SEM of 3.5   2   106 for PBS-injected
mice vs. 12.2   4   106 for TSLP-injected mice
[P   0.001] after 3 wk) and spleen (mean   SEM of 8   4   106 for PBS-injected mice vs. 14   5.4   106 for TSLP-injected mice [P   0.003] after 1
wk of treatment and a mean   SEM of 15   4   106 for PBS-injected mice vs. 52   12   106 for TSLP-injected mice [P   0.0001] after 3 wk). No
change was seen in the BM. All mice were age matched and no sex-related differences were noted.  c/TSLPR DKO mice did not respond to TSLP injec-
tions (closed triangles). (E) Photograph indicating thymic size in  c KO mice after wk of treatment with PBS or TSLP (top) and a histological analysis of
these tissues by hematoxylin and eosin staining (bottom).TSLP Promotes CD4  T Cell Development 164
HSA, BP-1, and IgM (not depicted). Peritoneal CD5  B1
cells were also present in similar numbers in both  c KO
and the  c/TSLPR DKO mice (Fig. 4 B, bottom). Consis-
tent with this,  c/TSLPR DKO mice did not have lower
serum IgM levels than those found in  c KO mice (Fig. 4
C). Thus, TSLP does not appear to regulate numbers of B1
cells nor affect IgM production.
To further examine the actions of TSLP, we evaluated
its effect on  c KO mice. Because of the sharing of IL-7R 
by the receptors for both IL-7 and TSLP, and the potential
for overlapping actions of these cytokines, we hypothesized
that  c KO mice that lack IL-7 signaling and have dimin-
ished thymocytes might exhibit hyperresponsiveness to
TSLP. 2-wk-old  c KO mice received 0.5- g daily i.p. in-
jections of PBS or TSLP for 1 or 3 wk. Strikingly, after 1
wk, TSLP treatment increased thymic cellularity 5–10-fold
in  c KO mice (Fig. 4 D, open rectangles vs. open ovals;
P   0.01), consistent with increased thymic size (Fig. 4 E,
top). Histological analysis showed that the thymus from  c
KO mice injected with PBS had a thin cortex, whereas
those from TSLP-injected mice had a wider cortex (Fig. 4
E, bottom). As expected, TSLP had no effect in  c/TSLPR
DKO mice (Fig. 4 D, closed triangles).
In addition to increased thymic cellularity, the fraction of
DP cells increased so that this was the most expanded thy-
mic population (Fig. 5 A, ii vs. i).  c KO mice injected
with TSLP for 3 wk still showed higher total thymic cellu-
larity than untreated mice (Fig. 4 D; P   0.01), albeit less
so than at 1 wk, with more CD4  SP T cells present (Fig. 5
A, x vs. ix). TSLP treatment for 1 wk also increased the to-
tal number of splenocytes (Fig. 4 D; P   0.01), mainly by
increasing B cells (Fig. 5 A, vi vs. v). After 3 wk of TSLP,
splenic cellularity further increased (Fig. 4 D; P   0.01). As
expected, this resulted in part from the expansion of B cells
(Fig. 5 A, xiv vs. xiii). The increase in B cells in the spleen
was also evident in the BM. Although the total BM cellu-
larity in  c KO mice was not increased by TSLP (not de-
picted), TSLP dramatically increased the B cell subpopula-
tions within 1 wk (Fig. 5 A, viii vs. vii), with immature B
cells being the most affected, increasing from  2 to 30% of
the total number of cells (see percent of B220  IgMlow cells
in Fig. 5 B). More mature stages also increased three- to
fourfold. However, these changes in B cell populations
were transient and at 3 wk of TSLP injection, these cells
diminished to the BM B lymphocyte cellularity seen in the
untreated mice (Fig. 5 A, xvi vs. xv, and B).
In addition to the increased B cells noted above, the in-
creased splenic cellularity was also partially due to an in-
crease in CD4  T cells (Fig. 5 A, xii vs. xi, and C). Consis-
tent with the age-dependent increase in CD4  T cells that
occurs in  c KO mice (19), control  c KO mice that were
injected with PBS for 3 wk versus 1 wk showed an age-
dependent increase in the percentage of CD4  T cells (Fig.
5 A, xi vs. iii). Approximately 5.4-fold more CD4  splenic
T cells were found in TSLP-treated  c KO mice than in
untreated mice (12.7   106 vs. 2.4   106), whereas the ab-
solute and relative increase in mature splenic CD8  T cell
numbers was less marked in TSLP-treated versus control
animals (3.8 fold, 2.4   106 vs. 0.63   106; Fig. 5 C). Al-
most all of the CD4  T cells in  c KO mice were TCRhigh
HSAlow and did not express the activation markers CD25
and CD69, and this was unaffected by TSLP treatment
(Fig. 5 D, top and middle). As previously shown, CD4  T
cells in  c KO mice primarily have a CD62Llow CD44high
Figure 5. TSLP can increase lymphoid subpopulations
in  c-deficient mice. (A) Flow cytometric analysis of  c
KO thymus, spleen, and BM 1 and 3 wk after injection
of PBS or TSLP. (B) B cell populations in the BM from
A (vii, viii, xv, and xvi). (C) TSLP injections induced an
increase in CD4  T cells (mean   SEM of 2.36  
1.48   106 for control mice vs. 12.7   6.7   106 for
TSLP-treated mice [P   0.0001], for a 5.4-fold in-
crease), CD8  T cells (mean   SEM of 0.63   0.43  
106 for control mice vs. 2.4   1.7   106 for TSLP-
treated mice [P   0.01], for a 3.8-fold increase), as well
as B cells (mean   SEM of 4.6   1.2   106 for control
mice vs. 27   7   106 for TSLP-treated mice [P  
0.0001], for a 5.9-fold increase) in the spleen of  c KO
mice 3 wk after injection. (D) Flow cytometric analysis
of splenic CD4  T cells in  c mice treated with PBS or
TSLP for 3 wk. TSLP increased the absolute numbers
of CD44high CD62Llow (mean   SEM of 2.3   1.2   106
for control  c mice vs. 11.3   4.106 for TSLP-treated
mice [P   0.0004], for 4.9-fold increase), CD44high
CD62Lhigh (mean   SEM of 0.4   0.2   106 for control
 c mice vs. 3.2   1.1   106 for TSLP-treated mice
[P   0.0003], for an eightfold increase), and CD44low
CD62Lhigh (mean   SEM of 0.08   0.06   106 for
control  c mice vs. 0.9   0.16   106 for TSLP-treated
mice [P   0.0001], for an 11-fold increase). (E)  c KO
mice were treated with PBS or TSLP for 1 wk and
injected with BrdU 10 and 16 h before being killed. BrdU incorporation was measured by intracellular staining using PE-labeled BrdU of the thy-
mocytes subpopulations. The number indicates the percent of BrdU  cells within the gated region.Al-Shami et al. 165
memory phenotype (20). Interestingly, TSLP increased the
number of CD62Lhigh CD44high cells, a population that has
been identified as central memory cells (21), the most (Fig.
5 D, bottom).
Above, we observed an increase in the number of CD4 
T cells, particularly in the spleen but also in the thymus.
Therefore, we examined the effect of TSLP on the prolif-
eration of thymocytes in vivo.  c KO mice treated with
PBS or TSLP for 1 wk were injected with BrdU 10 or 16 h
before being killed. TSLP increased BrdU incorporation in
all thymic subpopulations (Fig. 5 E). Interestingly,  c KO
CD4  SP thymocytes had the lowest basal level of BrdU
incorporation but were the most responsive to TSLP treat-
ment, increasing their proliferation approximately fourfold.
TSLP Cooperates with Anti-CD3 to Preferentially Expand
CD4  T Cells by Affecting Proliferation and Survival. To
clarify the mechanism by which TSLP promotes thymocyte
expansion, we treated SP WT thymocytes with anti-CD3 
with or without IL-7 or TSLP in vitro (Fig. 6 A). TSLP
alone had no significant effect, but when combined with
anti-CD3 , it markedly increased the proliferation of CD4 
SP thymocytes, whereas its effect on CD8  SP thymocytes
was much less (Fig. 6 A, top), suggesting that TSLP favors
the expansion of CD4  thymocytes. In contrast, IL-7 en-
hanced proliferation of both CD4  and CD8  SP thy-
mocytes alone or in combination with anti-CD3  (Fig. 6 A,
bottom), and overall, IL-7 was more potent than TSLP
even for CD4  thymocytes (note the difference in scale in
the top and bottom panels of Fig. 6 A). Correspondingly,
TSLP preferentially enhanced the survival of CD4  thy-
mocytes, whereas IL-7 had similar effects on the viability of
CD4  and CD8  thymocytes (Fig. 7 A). TSLP and IL-7
were equally potent in increasing the survival of DN and
DP thymocytes (not depicted). Consistent with its effect on
CD4  SP thymocytes, TSLP treatment preferentially en-
hanced TCR-induced proliferation (Fig. 6 B) and survival
(Fig. 7, B and C) of CD4  splenic T cells compared with
CD8  T cells. We observed a dramatic dilution of CFSE in
response to TSLP in both thymic and splenic CD4  (Fig. 6
C). Correspondingly, the percent of viable cells was in-
creased (Fig. 7, A and B) and the percent of annexin V /
7-AAD  cells (Fig. 7 C) was decreased by TSLP.
TSLP Is Required for Efficient Expansion of Murine CD4  T
Cells In Vivo. Compared with CD4  T cells from WT
mice, CD4  T cells from TSLPR KO mice exhibited less
expansion during the 7-d period after injection into suble-
thally irradiated recipient  c KO mice (Fig. 8 A). This indi-
cates that TSLP signaling is critical for an efficient expan-
sion of CD4  lymphocytes. In contrast, CD8  T cells from
both WT and TSLPR KO expanded to a similar degree
(Fig. 8 A). CFSE staining on day 3 showed the typical four
to five divisions in WT CD4  T cells (Fig. 8 B, top left);
however, TSLPR KO CD4  T cells persisted but had un-
dergone fewer cell divisions (Fig. 8 B, top right). In con-
trast, CD8  T cells from WT and TSLPR KO mice were
similar in their CFSE profiles. Taken together, our results
indicate that TSLP preferentially enhances both the expan-
sion and survival of CD4  T cells both in vitro and in vivo.
Discussion 
TSLP was discovered as a cytokine that could support
the ability of pre–B cells to differentiate into more mature
IgM  B cells, whereas IL-7 promotes development only to
an IgM  stage (5). Colonies emerging from murine B220 
IgM  BM cells develop into IgM  cells after 7 d of culture
in TSLP (22). In contrast, TSLP was previously shown to
play only a minimal role in murine T lymphopoiesis by in-
ducing proliferation of DN thymocytes, but only in an IL-
1–dependent manner (22).
Figure 6. TSLP preferentially expands CD4   T
cells. In A and B, cells were treated with medium,
100 ng/ml IL-7, or 100 ng/ml TSLP, and/or 2  g/ml
anti-CD3  antibodies. (A) In vitro proliferation of puri-
fied CD4  and CD8  SP thymocytes from WT mice.
Results are expressed as mean   SEM for four experi-
ments. TSLP increased anti-CD3 –induced proliferation
of CD4  SP cells (P   0.02), but did not significantly
affect CD8  SP expansion to anti-CD3  (P   0.07).
IL-7 significantly enhanced anti-CD3 –induced ex-
pansion of both CD4  and CD8  SP thymocytes (P  
0.0001 for both). (B) In vitro proliferation of purified
CD4  and CD8  splenocytes (prepared by positive se-
lection) treated as described above. TSLP significantly
increased anti-CD3 –induced proliferation of mature
CD4  T cells (P   0.0002), but not of CD8  T cells
(P   0.1). IL-7 significantly enhanced anti-CD3 –
induced expansion of both CD4  and CD8  mature T
cells (P   0.008 and 0.0005, respectively). (C) CD4 
thymocytes and splenic T cells were labeled with CFSE
and cultured for 1 wk with anti-CD3  with or without
TSLP, and cells were analyzed by flow cytometry. As
evaluated by decreased CFSE staining, TSLP increased
anti-CD3 –induced proliferation of CD4   but not
CD8  T cells. WT corresponds to the “open” curve,
whereas TSLPR KO mice are shown in solid black.TSLP Promotes CD4  T Cell Development 166
To clarify TSLP function, we now have studied
TSLPR-deficient mice and looked at effects of TSLP in
vivo and in vitro. Despite ubiquitous expression, TSLPR is
not required for the physical development and fertility of
mice. In addition, TSLPR KO mice exhibit normal my-
eloid, lymphoid, dendritic cell, and NK cell numbers, at
least in part due to the continuous action of IL-7. To ex-
amine the role of TSLP in lymphopoiesis, TSLPR KO
mice were crossed to  c KO mice. Inactivating TSLP sig-
naling in  c KO mice further reduced the cellularity of the
thymus, spleen, and BM, suggesting that TSLP can pro-
mote T and B cell expansion. Nevertheless, the existence
of lymphocytes in these DKO mice indicates that other
growth factors also contribute and that TSLP is not the
only factor responsible for the lymphoid cells present in
IL-7– and  c-deficient animals. Other cytokines, such as
stem cell factor and Flt3 ligand, presumably play a role (23,
24). We also examined cellular recovery after sublethal irra-
diation of TSLPR versus WT mice. The defective cellular
restoration in TSLPR KO mice suggests a role for TSLP in
recovery from lymphopenia. Moreover, the defect was also
more severe in TSLPR than WT mice injected with neu-
tralizing antibodies to IL-7, indicating that TSLP has at
least some actions that are independent of IL-7. As in our
study, other investigators found no significant developmen-
tal abnormality in TSLPR KO mice (25). Interestingly,
however, in Jak3/TSLPR DKO mice, they observed a de-
crease in B cells in the spleen but not in the BM, and saw
no change in T cells. In contrast, in our analysis of  c/
TSLPR DKO mice, total cellularity declined with marked
decreases in both B and T cells, findings that are consistent
with a role for TSLP in  c-independent expansion of both
of these lineages.
Figure 7. TSLP promotes survival of CD4  T cells. (A) In vitro survival of
purified CD4  and CD8  SP thymocytes from WT mice. The percent of
viable cells (mean   SEM for four experiments) was determined after 1 wk
by trypan blue exclusion. TSLP increased anti-CD3 –induced survival
of CD4  cells (P   0.02), but did not significantly affect CD8  survival
(P   0.24). IL-7 significantly enhanced anti-CD3 –induced survival of
both CD4  and CD8  thymocytes (P   0.03 and P   0.0001, respec-
tively). (B) In vitro survival assay of purified CD4  and CD8  splenic T
cells from WT mice. The percent of viable cells was determined by trypan
blue exclusion. Results are expressed as mean   SEM for five experi-
ments. TSLP significantly increased anti-CD3 –induced survival of
CD4  (P   0.0001) but not CD8  T cells (P   0.21). IL-7 significantly
enhanced anti-CD3 –induced survival of both CD4  and CD8  T cells
(P   0.001 and P   0.0001, respectively). (C) Purified CD4  and CD8 
splenocytes cultured as indicated were stained with annexin V and 7-AAD.
Figure 8. TSLP mediates efficient expansion of CD4  T cells. CD4  T
cells were isolated from WT or TSLPR KO mice and labeled with CFSE
before being injected into irradiated  c KO mice. (A) After 1 wk, TSLPR
KO CD4  T cells expanded less than CD4  T cells from WT mice (P  
0.008). CD8  T cells from WT or TSLPR mice expanded to a similar
degree. (B) Examination of the CFSE dilution on day 3 by flow cytometry
revealed that WT CD4  T cells were expanding more rapidly than TSLPR
KO CD4  T cells. No differences were observed for CD8  T cells.Al-Shami et al. 167
TSLP promoted B cell maturation in  c mice to the
B220  IgM  stage. It also enhanced B cell maturation in
WT mice to an almost identical level as IL-7, similar to
what was reported in neonatal WT mice injected with
TSLP (22). Interestingly, B progenitor cells in the BM of  c
KO mice expanded and matured when animals were in-
jected daily with TSLP for 1 wk, but the effect was transient
and no longer observed after 3 wk of TSLP. TSLP had less
of an effect in WT mice. A recent report using mice defi-
cient in IL-7, IL-7R , and  c on a TCR-  KO background
indicated that TSLP promoted the expansion of fetal liver–
derived pro–B cells but displayed no activity on adult BM-
derived pro–B cells (17), which perhaps suggests that our
findings in  c KO mice might reflect the changing potentials
of the progenitor population in these young animals.
A distinctive action of IL-7 is its ability to increase sur-
vival of immature thymocytes and provide a proliferative
signal in the pre–T cell stage after TCR-  rearrangement
(26). IL-7 is also essential for    TCR generation (27). Al-
though TSLP could not rescue     T cell development
when it was injected into  c KO mice (not depicted), like
IL-7, TSLP could promote the survival and proliferation of
T cells as well as B cells from WT mice. Strikingly, TSLP
preferentially increased TCR-mediated proliferation of
CD4  CD8  thymocytes and CD4  peripheral T cells in
vitro (Fig. 6), and the absence of TSLP signaling hinders
the expansion of these cells in vivo in the adoptive transfer
experiment (Fig. 8). The modest effect of TSLP on total
thymocyte and splenocyte numbers in WT mice (Fig. 2)
might be related to the presence of IL-7, which not only
promotes CD8   T cell homeostasis, but also increases
CD4  T cell survival (28). It is also possible that the T cell
compartment is already “filled,” allowing less expansion.
Alternatively, the cells might be less responsive if they have
already received signals from  c-dependent cytokines, so
that a potentially redundant signal from TSLP would have
little effect. Interestingly, two other  c-dependent cyto-
kines, IL-7 and IL-15, preferentially induce an expansion
of CD8  T cells rather than CD4  T cells (29–31). Like
IL-7 and IL-15, TSLP activates Stat5a and Stat5b (14, 32).
However, Stat5a and Stat5b transgenic mice generated in
our lab show an increase in CD8  T cells (33, 34), suggest-
ing that Stat5 by itself is unlikely to be mediating the pref-
erential effect of TSLP in expanding CD4  T cells.
Unlike IL-7, TSLP had no effect on the in vitro prolifer-
ation of thymocytes unless combined with TCR activation.
Because the differentiation of DP thymocytes into SP cells is
based on MHC specificity of their TCR signal and the
strength of the TCR engagement (35), it is conceivable that
TSLP provides a selective costimulatory signal that favors
the CD4  CD8  intermediate stage by enhancing the acti-
vation of these cells. Moreover, it is possible that TSLP
competes with IL-7 for the IL-7R  subunit, thus hindering
the ability of IL-7 to promote CD8  T cell expansion in
WT mice. Interestingly, IL-7 has been suggested to be im-
portant as a survival factor for CD4  memory T cells (28).
Thus, TSLP and IL-7, both of which share IL-7R , appear
to be important for CD4  T cell homeostasis. In  c KO
mice where IL-7 signaling is defective, the ability of TSLP
to promote the expansion of CD4  cells could be enhanced.
Interestingly, a recent report showed that human TSLP in-
directly promotes CD4  T cell homeostasis through the ac-
tivation of dendritic cells (36). Our results in the murine
system with purified CD4  and CD8  SP thymocytes, as
well as with splenic T cells, suggest a direct effect of TSLP
on CD4  T cells. Surprisingly, TSLP transgenic mice were
reported to exhibit diminished lymphopoiesis and my-
elopoiesis, with decreased T and B cell precursors (37).
These findings are different from ours, suggesting that TSLP
may have complex roles in vivo, depending on the temporal
and quantitative level of expression of TSLP.
In conclusion, TSLP is a type I cytokine that regulates
the growth and function of lymphocytes. Although its role
for B cell growth has been better appreciated, we now pro-
vide evidence that murine TSLP also plays a role in T cell
expansion both in vitro and in vivo, particularly of CD4  T
cells, suggesting that murine TSLP may play a role in
CD4  T cell homeostasis. This preferential action of TSLP
for CD4  versus CD8  T cells may also explain the relative
increase in CD4  T cells in  c KO mice, which might re-
flect the inactivation of signaling by IL-7 and IL-15 (which
favor expansion of CD8  T cells), coupled to the “unop-
posed” action of TSLP. Finally, it will be interesting to in-
vestigate whether TSLP may have usefulness in increasing
CD4  T cells in immunodeficient states.
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